CN104334190A - Autoimmune antibodies - Google Patents

Autoimmune antibodies Download PDF

Info

Publication number
CN104334190A
CN104334190A CN201380027063.XA CN201380027063A CN104334190A CN 104334190 A CN104334190 A CN 104334190A CN 201380027063 A CN201380027063 A CN 201380027063A CN 104334190 A CN104334190 A CN 104334190A
Authority
CN
China
Prior art keywords
seq
autoantibody
peptide
level
people experimenter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380027063.XA
Other languages
Chinese (zh)
Inventor
P·伯恩特
B·克卢格哈默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN104334190A publication Critical patent/CN104334190A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention generally relates to biomarkers associated with NSCLC, and methods and compositions for the detection and diagnosis of non-small cell lung cancer in a human subject.

Description

Autoimmune antibody
Invention field
The invention provides and have the method for the patient of nonsmall-cell lung cancer for the identification of benefiting from diagnosis that Erlotinib (Erlotinib) treats most, it is included in the serum of described patient and detects autoantibody.
Background of invention
a kind ofly have Orally active, strong EGF-R ELISA (EGFR) tyrosine kinase (TKI) inhibitor.
Erlotinib hydrochlorate is in active component, ratify as single therapy after chemotherapy for advanced Non-small cell lung (NSCLC) patient, be used for the patient of chemotherapeutic period without (two/tri-lines maintain) after development (line maintain) or chemotherapy failure as maintaining treatment. also ratify the patient comprising the sudden change of EGFR activity as first-line treatment for its tumor in EU.
Unusual protein expression is common in cancer and viral infection.Immune system contains a specialised branch, it identifies that (neoantigen (neo-antigen) also effectively eliminates the cell of expressing these neoantigens to the protein of being induced by cell transformation, does not have to set up the tolerance for neoantigen between the period of development.Think that this branch immune is effective for the transforming mutant of viral infection, the spontaneous chromosome caused by the mistake of cell division mechanism and genome rearrangement or carcinogen induction.Although initial cell toxic immune Ying Da – its pass through CD8 +t cell to the identification Jie Dao – of the unusual protein that MHCI complex is shown fast and effectively, the lasting response for viral infection or abnormal cell clone needs CD4 +the common stimulating effect of t helper cell, CD4 +the MHCII complex that t helper cell is delivery cell through professional antigen activates after presenting the outer peptide of born of the same parents (it can come from the cell of cracking in the first stage of cytotoxic immune response).In addition, these cells can induce the lasting B cell for virus or abnormal protein to reply and antibody.In colorectal cancer, show a large amount of CD8 +t cell infiltrate tumors is than traditional tumour better prognostic marker (Koizumi, Hojo etc. 2007 by stages 1), and in nearly all principal entities cancer, it is associated with favourable prognosis, regardless of cancer cell-types.
Autoantibody is known, the diagnostic entity in cancer.Many cancer autoantibodys are the protein of expressing in embryonal tissue under normal circumstances, therefore represent " external " protein, do not have to set up the immunologic tolerance for them.Cancer history causes humoral immunoresponse(HI) in these protein leakage to blood flow late period.A typical example is common cancer markers CEA (carcinoembryonic antigen).Tumor frequently represents the protein processing of mistake.Outstanding example comprises the protein being subject to the incorrect cutting of celluar localization protease (autoantibody existed for p53N terminal sequence is one of the most specific biomarker of pulmonary carcinoma, determines to cut N terminal sequence to core under normal circumstances at this protein target) or being subject to the incorrect glycosylation of cellular glycosylation enzymes (the anti-MUC1 antibody for the MUC1 of incorrect O-glycoforms is the biomarker of kinds cancer).Although frequently observe p53 sudden change in tumor, autoantibody almost always holds – the immunogenicity of p53 and the short-lived under normal circumstances and ectopic expression being positioned the protein of core to be connected more for the N of this protein for the specificity of this protein.
Li etc. 2describe the detection of natural EGFR autoantibody in the serum of NSCLC patient.Li etc. 3with Chapman etc. 4describe the detection of the NAA for p53, HER2, NY-ESO-1, CAGE, MUC1 and GBU4-5.And, WO2011073905 5relate to and be developed to the relevant tumor markers of higher developmental stage with Cancerous disease from lower developmental stage.
Unusual (sudden change or with abnormal quantity or localization and expression) oncoprotein mass-energy causes antibody response.Frequently observe the autoantibody of tumor inducing, and investigate their effectiveness (Albert and Darnell 2004 as diagnosis marker 6).Have the remarkable specific autoantibody for oncoprotein matter although can find, their great majority lack the sensitivity that diagnostic test needs.
This area knows that minority predicts the epidemiology that Erlotinib hydrochlorate responds and genetic marker reliably.Especially, the EGFR sudden change described in exons 1 8-21 (the intracellular kinase territory of receptor) to be related (Paz-Ares, Soulieres etc. 2010 with good prognosis and with good response for the treatment of TKI 7).The current unique predicting marker (sudden change of EGFR activity) known is difficult to diagnosis, because need tumor biopsy.At present, only have an appointment 50% NSCLC patient with biopsy diagnosis (Reck, Hermes etc. 2011 8).Clearly need simpler technology to detect the predicting marker of TKI effect.Wanting the qualification respondent when diagnosing, having made patient as much as possible benefit from Erlotinib treatment as early as possible, simultaneously for the patient of unlikely response explores other treatment option.
Detailed Description Of The Invention
The problem that the present invention solves is a kind of method providing cancer diagnosis in people experimenter.
The problem that the present invention solves is a kind of method providing diagnosing non-small cell lung cancer in people experimenter.
The problem that the present invention solves is a kind of method providing diagnosing non-small cell lung cancer in people experimenter, and it is undertaken by providing the antibody for mutant egf R sequence.
The patient identified by methods described herein is for responding Erlotinib treatment or its pharmaceutically acceptable salt, the particularly patient of Erlotinib hydrochlorate, particularly NSCLC patient.
We find that autoantibody of the present invention has the sensitivity of diagnostic test needs surprisingly, especially for the autoantibody of mutant egf R sequence.
EGFR is bonded to cell membrane under normal circumstances and does not come off into blood flow.EGFR is a kind of Normal adult protein, finds in a large number in some adult tissues.Expection can set up the immunologic tolerance for this protein and its many variants.Nearly all sequence belongs to the cytosolic fractions of molecule and professional antigen is delivery cell can't see.Sudden change only affects the sub-fraction of EGFR molecule.
Unless otherwise defined, all terms used herein have and generally understand identical implication with those skilled in the art of the invention.
Term " represents the level of the described autoantibody of health population people experimenter " refers to not suffer from the valuation of the average level of the autoantibodies in serum of the PATIENT POPULATION of NSCLC.
Term " represents the level of the described autoantibody of NSCLC patient " refers to suffer from the valuation of the average level of the autoantibodies in serum of the PATIENT POPULATION of NSCLC.
Term " overall survival (OS) " refers to from medical diagnosis on disease, the time span of treatments period and afterwards patients survive.Just as technical staff will assent, if patient belongs to patient's subgroup compared with another patient's subgroup with the statistically significant longer average time-to-live, so the overall survival of this patient improves or strengthens.
Term " progresson free survival (PFS) " refers to from medical diagnosis on disease, treatments period and afterwards, and according to the assessment of attending doctor or investigator, the disease of patient does not become poorer, the time span namely do not developed.Just as technical staff will assent, if patient belongs to the patient's subgroup having longer time disease not develop compared with the average of the matched group of situation similar patients or average progresson free survival time, so the progresson free survival of this patient improves or strengthens.
Term " patient " refers to any single mammal wanting to treat.Especially, " patient " is people experimenter.More particularly, patient is the people experimenter of suffers from cancer, particularly NSCLC.
The class protein that term " autoantibody " manufactures for one or more patient's oneself protein matter for patients immune system.
Term " aminoacid " represents the carboxyl a-amino acid of one group of natural generation, comprise alanine (three-letter codes: ala, using single letter code: A), arginine (arg, R), agedoite (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), with valine (val, V).
As used in this article, " therapy " or " treatment " (and grammatical variants) refer to attempt to change treat the clinical intervention of the natural process of disease in individuality, and can in order to prevent or implement during clinical pathology process.The therapeutic effect wanted includes but not limited to prevent disease and occurs or occur, any direct or indirect pathological consequences, the prevention transfer of relief of symptoms, weakening disease, reduces disease progression speed, improves or the state and eliminate or improve prognosis of palliating a disease.
As used in this article, term " gene " comprises the variant of gene.Term " variant " relates to the nucleotide sequence substantive similar to the nucleotide sequence provided by GenBank accession number.Those skilled in the art can understand term " substantive similar " preferably.Especially, genetic mutation can be show the allele that nucleotide exchanges compared with allelic nucleotide sequence most popular in crowd.Preferably, this type of substantive analogous nucleic acid sequences and most popular allele have at least 80%, and preferably at least 85%, more preferably at least 90%, the most preferably sequence similarity of at least 95%.Term " variant " is also intended to relate to splice variant.
Term " sudden change " refers to the change in genome sequence.These random sequences can be defined as burst in cell and spontaneous change.Sudden change can cause several dissimilar changes in sequence; These can not affect, and change the product of gene, or stop gene correctly or completely to play function.Term " somatic mutation " refers in hereditary constitution neither inherit the change also can not passing to offspring obtained.
As used in this article, phrase " recommend treatment " refer to use generate to relate in the sample of patient the level of biomarker or autoantibody or the information of existence or data to identify that patient is applicable to or is not suitable for using certain therapy for treating.In some embodiments, described therapy can comprise medicine.Described information or data can be any forms, written, oral or electronics.In some embodiments, use the information generated or data to comprise reception and registration, present, report, store, send, shift, supply, transmit, send, distribute or its combination.In some embodiments, pass on, present, report, store, send, shift, supply, transmit, send, distribute or its combination by accountant, analytic unit or its combination implement.In some further embodiments, pass on, present, report, store, send, shift, supply, transmit, send, distribute or its combination is implemented by laboratory or medical professional.In some embodiments, described information or data comprise the level of described biomarker or autoantibody and comparing of reference level.In some embodiments, described information or data comprise in sample the instruction that there is or lack described biomarker or autoantibody.In some embodiments, described information or data comprise patient and are applicable to or are not suitable for the instruction with the therapy for treating comprising described medicine.In some embodiments, described therapy is Erlotinib.
As used in this article, phrase " provide diagnosis " and refer to use generate to relate in the sample of patient the level of biomarker or autoantibody or the information of existence or data to diagnose the disease in patient.Described information or data can be any forms, written, oral or electronics.In some embodiments, use the information that generates or data to comprise to present, report, store, send, shift, supply, transmit, send, distribute or its combination.In some embodiments, present, report, store, send, shift, supply, transmit, send, distribute or its combination by accountant, analytic unit or its combination implement.In some embodiments, present, report, store, send, shift, supply, transmit, send, distribute or its combination is implemented by laboratory or medical professional.In some embodiments, described information or data comprise the level of described biomarker or autoantibody and comparing of reference level.In some embodiments, described information or data comprise in sample the instruction that there is or lack described biomarker or autoantibody.In some embodiments, described information or data comprise the instruction that patient diagnosis has described disease.In some embodiments, described disease is nonsmall-cell lung cancer.
During TASK research, have collected biopsy material and somatic mutation the most frequently tests to tumor cell there is situation, namely exons 19 is deleted and exon 21 point mutation.During TASK research, have collected blood serum sample at multiple time point (before administration, the 8th day, the 22nd day and development) from all patients and have evaluated the autoantibody for EGFR.
In these patients, prediction rash occurs or to get nowhere or autoantigenicity peptide sequence that overall survival extends must comprise and a set ofly to derive from EGFR sequence, starts from the 737th and extends through the sequence of the 756th.These peptides comprise some sequence variants, but must comprise the sequence (table 2) of the deletion with 746-750 position or vicinity.
This corresponds to the position of the deletion in exons 19 somatic mutation just, and its indication known comes from outstanding effect (Rosell etc. 2009 of TKI treatment 9, Mok etc. 2009 10).
In tumor tissues Exon 19, body cell EGFR suddenlys change and produces protein variants, and immune system does not form tolerance for it.This somatic mutation only occurs over just in tumor, therefore, if it induces autoantibody, can detect in the serum of patient, it can be used for drawing to there is about in NSCLC tissue the conclusion that exons 19 suddenlys change or exon 21 suddenlys change, and its prediction progresson free survival known extends and tyrosine kinase monotherapy is better than chemotherapy (Heigener and Reck 2011 11).
The Standard blood sample detection autoantibody from patient can be used, without the need to obtaining tumor cell with biopsy.This is a larger advantage relative to present practice, because the response rate of useful tumor sample is also no more than 50% (Reck, Hermes etc. 2011 even in clinical studies 12).
Can detect high (Fig. 1) in the concentration ratio normal healthy controls of anti-EGFR autoantibody in the blood sample of NSCLC patient.Especially, identify peptide sequence, produce the continuum with high immunogenicity, between patient and normal healthy controls serum, there is larger difference.Identify continuous sequence section, be wherein greater than 8 (tables 1) more than the ratio of peptide signal various in the cancer patient of 30% to the maximum in contrast.
Protein Sequence area The consensus sequence of autoantigenicity peptide in this region
EGFR 323-336 VRKSKKSEGPSxKV
EGFR 546-564 PREFVENSECIQCHPECL
EGFR 574-591 RGPDNCIQCAHYIDGPHCVKTCP
EGFR 735-762Del 1 GEKVKIPVAIK[-S]PKANK
EGFR 739-758Del 2 KIPVAIK[-HRK]PTSPK
EGFR 793-806 MPFGCLLDYVREH
EGFR 867-883 KEYHAEGGKVPIKWM
EGFR 986-1002 RMHLPSPTDSNFYRA
EGFR 1081-1095 SIDDTFLPVPEYIN
EGFR 1148-1166 NSTFDSPAHWAQKGSHQI
Table 1: the continuous EGFR sequence in NLSCL patient with high autoantigenicity
Above-mentioned sequence can be used for the early diagnosis of NSCLC.
Regression analysis identifies significant evidence and shows to affect progresson free survival (PFS) and overall survival (OS) the two (Fig. 2) for the existence of the antibody of described peptide.Although the number of sample is little compared with the number of peptide, need to consider many co-variation amounts and various peptide none reach enough statistical significance, but we find that the many candidates likely obtained after univariate analysis select relevant peptide when combining the overlay information from various independent statistics way surprisingly.Fig. 3 display makes the process selecting the candidate sequence listed in table 2.The sequence listed in table 2 or its to be longer than 8 amino acid whose any continuous subsequences be candidate sequence.
Table 2: the antigenic sequence affecting NSCLC patient PFS and OS
KVKIPVAIKELREATSPKA Explain
KVKIPVAIK------APKA 737_V003
KVKIPVAIK---APTS 737_V004
KVKIPVAIKD------PKA 737_V007
KVKIPVAIKELKA 737_V015
KVKIPVAIKE------PKA 737_V019
KVKIPVAIKEQKA 737_V024
KVKIPVAIKESKA 737_V029
KVKIPVAIKEV-----PK 737_V037
KVKIPVAIK------IPKA 737_V039
KVKIPVAIK------SPKA 737_V054
KVKIPVAIK------TPKA 737_V057
--KIPVAIKE----ASPKA 739_V010
--KIPVAIKEF----SPKA 739_V013
--KIPVAIKE----NSPKA 739_V027
--KIPVAIK----VASPKA 739_V067
--KIPVAIK----VPSPKA 739_V070
Table 3: have the example of the peptide sequence of high potential predictability to the progresson free survival extended there is having in the patient of EGFR sudden change of rash
The EGFR peptide sequence being selected from Seq.Id.No.1-Seq.Id.No.15 is the continuous sequence having high autoantigenicity in NLSCL patient.
The generation of the adverse events (as rash) that the EGFR peptide sequence being selected from Seq.Id.No.16-Seq.Id.No.517 is treated for Erlotinib for prediction and rank are useful.
Be selected from the EGFR peptide sequence of Seq.Id.No.518-Seq.Id.No.602 for impact, particularly extend NSCLC patient to get nowhere and the antigenic sequence of overall survival, particularly mutant egf R peptide sequence Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559 and Seq.Id.No.560, and EGFR peptide sequence Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521 and Seq.Id.No.561.
The EGFR peptide sequence being selected from Seq.Id.No.603-Seq.Id.No.619 has high potential predictability having in the patient of EGFR sudden change of generation rash to the progresson free survival extended.
If they are present in patient, the antibody for these peptide sequences most possibly affects PFS and OS.Detect the test that these antibody in patients serum exist situation to can be used for guiding treatment and triage is entered each treatment group.
The invention provides a kind of method of diagnosing non-small cell lung cancer in people experimenter, it comprises: the level measuring the autoantibody being selected from the autoantibody group identifying mutant human EGFR in the blood sample of this people experimenter, and the level being selected from the autoantibody of the autoantibody group identifying mutant human EGFR described in the blood sample of wherein this people experimenter raises and indicates nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter.
Some embodiments of the present invention provide methods described herein, wherein measure the level of the autoantibody identifying mutant human EGFR.
Some embodiments of the present invention provide methods described herein, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7, Seq.Id.No.15, Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516, Seq.Id.No.517, Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599, Seq.Id.No.601, Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
Some embodiments of the present invention provide methods described herein, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7 and Seq.Id.No.15.
Some embodiments of the present invention provide methods described herein, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516 and Seq.Id.No.517.
Some embodiments of the present invention provide methods described herein, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599 and Seq.Id.No.601.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619..
Some embodiments of the present invention provide methods described herein, and wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, and Seq.Id.No.561.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, and Seq.Id.No.560.
Some embodiments of the present invention provide methods described herein, and in the blood sample of wherein this people experimenter, the level of autoantibody is higher than the level of the described autoantibody representing health population people experimenter 5 times.
Some embodiments of the present invention provide Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate, it is used for the treatment of the NSCLC patient identified by methods described herein, comprises and uses Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate to this patient.
Some embodiments of the present invention provide autoantibody for predicting that NSCLC patient is to Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate, and the purposes of the response for the treatment of, this antibody is identified by methods described herein.
Some embodiments of the present invention provide a kind of for detecting the test kit that one or more are selected from the level of the autoantibody of the autoantibody group identifying mutant human EGFR in the blood sample of people experimenter, and the level being selected from the autoantibody of the autoantibody group identifying mutant human EGFR described in the blood sample of wherein this people experimenter raises and indicates nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter.
Some embodiments of the present invention provide test kit described herein, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7 and Seq.Id.No.15.
Some embodiments of the present invention provide test kit described herein, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516 and Seq.Id.No.517.
Some embodiments of the present invention provide test kit described herein, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599 and Seq.Id.No.601.
Some embodiments of the present invention provide test kit described herein, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
Some embodiments of the present invention provide test kit described herein, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, and Seq.Id.No.560.
Some embodiments of the present invention provide test kit described herein, and wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, and Seq.Id.No.561.
Some embodiments of the present invention provide a kind of method of diagnosing non-small cell lung cancer in people experimenter, and it comprises:
The level of the autoantibody being selected from the autoantibody group identifying Human epidermal growth factor receptor is measured in the blood sample of this people experimenter, the level being selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor described in the blood sample of wherein this people experimenter raises and indicate nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter, particularly the level of the wherein autoantibody of measurement identification Human epidermal growth factor receptor.
Some embodiments of the present invention provide method mentioned above, and wherein said autoantibody identification is selected from the EGFR peptide of lower group:
Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.3, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7, Seq.Id.No.8, Seq.Id.No.9, Seq.Id.No.10, Seq.Id.No.11, Seq.Id.No.12, Seq.Id.No.13, Seq.Id.No.14, Seq.Id.No.15, Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.64, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.102, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.309, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.370, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.373, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516, Seq.Id.No.517, Seq.Id.No.518, Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.525, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.561, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.566, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599, Seq.Id.No.600, Seq.Id.No.601, Seq.Id.No.602, Seq.Id.No.603, Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618, and Seq.Id.No.619.
Some embodiments of the present invention provide method mentioned above, wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.3, Seq.Id.No.8, Seq.Id.No.9, Seq.Id.No.10, Seq.Id.No.11, Seq.Id.No.12, Seq.Id.No.13, Seq.Id.No.14, Seq.Id.No.64, Seq.Id.No.102, Seq.Id.No.309, Seq.Id.No.370, Seq.Id.No.373, Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, Seq.Id.No.525, Seq.Id.No.556, Seq.Id.No.558, Seq.Id.No.561, Seq.Id.No.566, Seq.Id.No.600, Seq.Id.No.602 and Seq.Id.No.603.
Some embodiments of the present invention provide a kind of for detecting the test kit of level that one or more are selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor in the blood sample of people experimenter, and the level being selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor described in the blood sample of wherein this people experimenter raises and indicates nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter.
Some embodiments of the present invention provide test kit mentioned above, wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.3, Seq.Id.No.8, Seq.Id.No.9, Seq.Id.No.10, Seq.Id.No.11, Seq.Id.No.12, Seq.Id.No.13, Seq.Id.No.14, Seq.Id.No.64, Seq.Id.No.102, Seq.Id.No.309, Seq.Id.No.370, Seq.Id.No.373, Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, Seq.Id.No.525, Seq.Id.No.556, Seq.Id.No.558, Seq.Id.No.561, Seq.Id.No.566, Seq.Id.No.600, Seq.Id.No.602 and Seq.Id.No.603.
Some embodiments of the present invention provide according to test kit as herein described, wherein said autoantibody identification is selected from Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, and the mutant egf R peptide of Seq.Id.No.560.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.518.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.519.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.520.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.521.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.522.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.523.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.524.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.525.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.526.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.527.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.528.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.529.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.530.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.531.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.532.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.533.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.534.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.535.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.536.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.537.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.538.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.539.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.540.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.541.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.542.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.543.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.544.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.545.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.546.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.547.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.548.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.549.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.550.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.551.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.552.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.553.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.554.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.555.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.556.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.557.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.558.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.559.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.560.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.561.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.562.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.563.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.564.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.565.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.566.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.567.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.568.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.569.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.570.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.571.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.572.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.573.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.574.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.575.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.576.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.577.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.578.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.579.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.580.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.581.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.582.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.583.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.584.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.585.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.586.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.587.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.588.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.589.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.590.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.591.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.592.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.593.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.594.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.595.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.596.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.597.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.598.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.599.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.600.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.601.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.602.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.603.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.604.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.605.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.606.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.607.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.608.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.609.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.610.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.611.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.612.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.613.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.614.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.615.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.616.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.617.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.618.
Some embodiments of the present invention provide methods described herein, wherein said autoantibody identification EGFR peptide Seq.Id.No.619.
Some embodiments of the present invention provide methods described herein, wherein measure the level of the autoantibody identifying p53.
Some embodiments of the present invention provide methods described herein, and in the blood sample of wherein this people experimenter, the level of autoantibody is higher than the level of the described autoantibody representing health population people experimenter 5 times.
Some embodiments of the present invention provide a kind of method for measuring EGFR mutation status in the tumor tissues of people experimenter suffering from nonsmall-cell lung cancer, and it comprises:
Detect in the blood sample of people suffering from nonsmall-cell lung cancer and be selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor peptide described herein, wherein exist during described autoantibody assignor organizes and there is exons 19 in the gene of the EGFR that encodes and suddenly change.
Some embodiments of the present invention provide a kind of method for measuring EGFR mutation status in the tumor tissues of people experimenter suffering from nonsmall-cell lung cancer, and it comprises:
Detect in the blood sample of people suffering from nonsmall-cell lung cancer and be selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor peptide described herein, wherein exist during described autoantibody assignor organizes and there is exon 21 in the gene of the EGFR that encodes and delete.
Some embodiments of the present invention provide Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate, it is used for the treatment of the NSCLC patient identified by methods described herein, comprises and uses Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate to this patient.
Some embodiments of the present invention provide autoantibody for predicting that NSCLC patient is to Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate, and the purposes of the response for the treatment of, this antibody is identified by methods described herein.
Some embodiments of the present invention provide a kind of for detecting the test kit of level that one or more are selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor in the blood sample of people experimenter, and the level being selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor described in the blood sample of wherein this people experimenter raises and indicates nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter.
Some embodiments of the present invention provide according to test kit as herein described, and wherein said autoantibody identification is selected from the EGFR peptide of Seq.Id.No.1-Seq.Id.No.15.
Some embodiments of the present invention provide according to test kit as herein described, and wherein said autoantibody identification is selected from the EGFR peptide of Seq.Id.No.16-Seq.Id.No.517.
Some embodiments of the present invention provide according to test kit as herein described, and wherein said autoantibody identification is selected from the EGFR peptide of Seq.Id.No.518-Seq.Id.No.602.
Some embodiments of the present invention provide according to test kit as herein described, and wherein said autoantibody identification is selected from the EGFR peptide of Seq.Id.No.603-Seq.Id.No.619.
Some embodiments of the present invention provide according to test kit as herein described, and wherein said autoantibody identification is selected from Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, and the EGFR peptide of Seq.Id.No.561.
Some embodiments of the present invention provide a kind of method of diagnosing non-small cell lung cancer in people experimenter, and it comprises:
A) in the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying mutant human EGFR,
B) level of more described autoantibody and reference level, and
C) diagnosis of nonsmall-cell lung cancer is provided when the level of described autoantibody exceeds reference level.
Some embodiments of the present invention provide a kind of method of diagnosing non-small cell lung cancer in people experimenter, and it comprises:
A) in the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying mutant human EGFR,
B) level of more described autoantibody and reference level, and
C) treatment is recommended when the level of described autoantibody exceeds reference level.
Some embodiments of the present invention provide method mentioned above, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, and Seq.Id.No.560.
Some embodiments of the present invention provide method mentioned above, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7, Seq.Id.No.15, Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516, Seq.Id.No.517, Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599, Seq.Id.No.601, Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
Some embodiments of the present invention provide method mentioned above, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7 and Seq.Id.No.15.
Some embodiments of the present invention provide method mentioned above, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.38 I, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516 and Seq.Id.No.517.
Some embodiments of the present invention provide method mentioned above, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599 and Seq.Id.No.601.
Some embodiments of the present invention provide method mentioned above, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
Some embodiments of the present invention provide method mentioned above, and in the blood sample of wherein this people experimenter, the level of autoantibody is higher than the level of the described autoantibody representing health population people experimenter 5 times.
Some embodiments of the present invention provide a kind of method of diagnosing non-small cell lung cancer in people experimenter, and it comprises:
A) in the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying Human epidermal growth factor receptor,
B) level of more described autoantibody and reference level, and
C) diagnosis of nonsmall-cell lung cancer is provided when the level of described autoantibody exceeds reference level.
Some embodiments of the present invention provide a kind of method of diagnosing non-small cell lung cancer in people experimenter, and it comprises:
A) in the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying Human epidermal growth factor receptor,
B) level of more described autoantibody and reference level, and
C) treatment is recommended when the level of described autoantibody exceeds reference level.
Some embodiments of the present invention provide method mentioned above, wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.3, Seq.Id.No.8, Seq.Id.No.9, Seq.Id.No.10, Seq.Id.No.11, Seq.Id.No.12, Seq.Id.No.13, Seq.Id.No.14, Seq.Id.No.64, Seq.Id.No.102, Seq.Id.No.309, Seq.Id.No.370, Seq.Id.No.373, Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, Seq.Id.No.525, Seq.Id.No.556, Seq.Id.No.558, Seq.Id.No.561, Seq.Id.No.566, Seq.Id.No.600, Seq.Id.No.602 and Seq.Id.No.603.
Some embodiments of the present invention provide method mentioned above, and in the blood sample of wherein this people experimenter, the level of autoantibody is higher than the level of the described autoantibody representing health population people experimenter 5 times.
Some embodiments of the present invention provide methods described herein, and wherein said treatment is Erlotinib.
Some embodiments of the present invention provide methods described herein, and wherein said treatment is Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate.
Accompanying drawing and sequence numbering
Fig. 1: by patient's (49 increment product, four figures) and contrast (one digit number) grouping, the logarithm conversion value of the peptide combination of all peptides.On average, patient has higher signal, has the combination of some antibody to peptide to be better than any signal in control serum.
Fig. 2: OS or PFS Cox regression model in rectangular histogram ~ EGFR+TRT+EGFR:TRT+SEX+ antibody titer+antibody titer: the TRT of p Distribution value of antibody titer significance.If antibody titer does not affect survival, so expection is uniformly distributed.Be highly significant to equally distributed departing from, this just reaches a conclusion, and in 245 antibody titers of p value <0.05, about 50% can have appreciable impact to progresson free survival.Close copy about overall survival (OS) calculates the candidate of generation 663 p value <0.05, False discovery rate slightly better, namely about 40%.
Fig. 3: Venn figure, shows the selected of the peptide candidate of (A) progresson free survival and (B) overall survival.Tai – is from the initial peptide selected works of Cox regression model with all co-variation amounts; Rash: carry out the overlapping sequences predicting the peptide of PFS (OS) in comfortable proportional hazard model in the patient with rash; TRT: carry out the overlapping sequences predicting the peptide of PFS (OS) in comfortable Erlotinib subgroup; EC4: the unit-variable analysis shows of response (4 all after dates, classification) antagonist titre.
Fig. 4: what test in branch, existence indication (p=0.006) for the autoantibody of mutant egf R peptide better treats final result, regardless of the generation of rash.
Table 4: Human epidermal growth factor receptor peptide Seq.Id.No.1-619, * indicate mutant egf R
Experiment
Peptide array
By PepStar tM(JPT Peptide Technologies GmbH, Berlin, Germany) peptide microarray platform creates peptide array, generating custom peptide microarray on microscope slide, for biomarker discovery, immunologic surveillance and detection and checking protein interaction.Through flexible joint immobilization peptide on a glass slide.Chemo-selective coupling generates microarray that is directed and covalent attachment peptide.
Synthesize the native peptides of 3661 kinds of regulations and 500 specific admixture control sequence (covering the sequence of EGF receptor, Arachidonate 15-lipoxygenase B (LX15B) and p53 and variant thereof), and print array.The EGFR using serum dilution 1:200 to detect in NSCLC Patient Sample A combines.Microarray incubation is implemented in 30 DEG C in automatization hybridization stations HS4800 (Tecan).After cleaning, detect with anti-human two anti-(JIR, 0.1 μ g/ml measures system final concentration) of Cy5 labelling the immunoglobulin G (IgG) combined.The microarray scanner GenePix (Molecular Devices) being furnished with automatic load apparatus 4200AL is used to read fluorescence.With Relative fluorescence units shows signal intensity.
Following table describes cleaning and incubation conditions in detail:
Confining liquid: SmartBlock Block buffer
For serum and two anti-diluent: SuperBlock T20 Block buffer
Cleaning buffer solution 1: 1x TBS+0.1％Tween 20
Cleaning buffer solution 2: 0.1x SSC+0.05％Tween 20
Table 5: experiment condition
Step Code Parameter Buffer
1 Cleaning 1x 1x TBS-0.1％Tween20
2 Probe injection 1 Confining liquid
3 Hybridization 1h，30℃
4 Cleaning 2x 1x TBS-0.1％Tween20
5 Probe injection 2 1:200 Patients serum
6 Hybridization 2h，30℃
7 Cleaning 3x 1x TBS-0.1％Tween20
8 Probe injection 3 Cy5-anti-human two resists
9 Hybridization 45min，30℃
10 Cleaning 2x 1x TBS-0.1％Tween20
11 Cleaning 3x 0.1x SSC-0.05％Tween20
12 Microscope slide is dry 20sec
13 Cleaning 3x 0.1x SSC-0.05％Tween20
14 Microscope slide is dry 5min
Table 6: experiment condition
Sample
Sample is selected from the patient belonging to TASK research.TASK studies 200 patient randomization, open label, an II phase, compares in a line NSCLC patient with the combination of (bevacizumab (bevazizumab)) and standard chemotherapy regimen (gemcitabine (gemcitabine) adds cisplatin (cisplatin) or Pa Litasai (paclitaxel) adds carboplatin (carboplatin)) add the further registration stopping this studying after the data of a preplanned interim analysis from 120 patients.As the generation of adverse events record rash.There is situation and have recorded mutation status the biopsy test EGFR sudden change from all patients.
For the research of peptide array, employ totally 49 patients (24 from Liang Ge branch with (A+T), 25 with chemotherapy (A+C)).In the patient for A+T branching selection, in 16 patients, there is rash.Comparatively speaking, only have 3 patients that rash occurs in A+C branch.This corresponds to expection rash frequency, because rash is brought out by Erlotinib, but chemotherapy only brings out very limited degree.
Clinical data can be obtained and comprise outcome data, such as, respond overall survival and progresson free survival and rash rank and EGFR mutation status (biopsy is measured before treatment).
Statistical analysis
Overall situation inspection
Application way below carries out data modeling:
Descriptive statistics (using suitable unitary variant) inspection, to identify the co-variation amount of the candidate as the linear regression model (LRM) describing performance parameter (PFS or OS)
For efficacy parameter qualification best model (survival analysis)
Be added into model by antibody titer and with the interaction for the treatment of and compare performance with new variables
Rely on selected a kind of universal model, in set of variables altogether interested, antagonist titre is tested:
EGFR suddenlys change (EGFRM), chest radiotherapy (TRT), the proportional hazard model of the efficacy parameter antagonist abundance (two low/high Feng Du – of sample product group – are divided by intermediate value) of rash
In A+T branch, wild type (WT+) interior antibody titer is to the U inspection of the respondent of respondent/not
EGFRM and TRT responds the chi-square criterion of (the 6th week, the 12nd week) antagonist abundance
Finally, the peptide sequence of the antibody titer of various closely similar generation height correlation is used.For the peptide sequence of great majority report, select consensus sequence (Smith-Waterman comparison similarity score >50 uses PAM30 to substitute matrix and Gap Penalty 1) from the list of all peptides with very high sequence similarity and antibody titer is associated with target thing titre (Spearman rank correlation >0.75).
1Koizumi,K.,S.Hojo,et al.(2007)."Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response."Cancer Science 98(11):1652-1658
2Li Yuan et al,Chinese Journal of Lung Cancer,13(7),2010,727-730
3Li Yuan et al,Chinese Journal of Lung Cancer,12(10),2009,1999-6187
4C J Chapman,A Murray,J E McElveen,U Sahin,U Luxemburger, Türeci,R Wiewrodt,A C Barnes,J F Robertson,“Autoantibodies in lung cancer:possibilities for early detection and subsequent cure”,Thorax2008；63(3):228-233
5WO2011073905
6Albert,M.L.and R.B.Darnell(2004)."Paraneoplastic neurological degenerations:Keys to tumor immunity."Nat.Rev.Cancer 4(1):36-44
7Paz-Ares,L.,D.Soulieres,et al.(2010)."Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations:pooled analysis."J Cell Mol Med 14(1-2):51-69
8Reck,M.,A.Hermes,et al.(2011)."Tissue sampling in lung cancer:A review in light of the MERIT experience."Lung Cancer 74(1):1-6
9Rosell et al.,N Engl J Med 2009；361:958-967
10Mok et al.,N Engl J Med 2009；361:947-957
11Heigener,D.and M.Reck(2011)."Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer:Impact on treatment beyond gefitinib and erlotinib."Advances in Therapy 28(2):126-133
12Reck,M.,A.Hermes,et al.(2011)."Tissue sampling in lung cancer:A review in light of the MERIT experience."Lung Cancer 74(1):1-6

Claims (41)

1. the method for diagnosing non-small cell lung cancer in people experimenter, it comprises:
In the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying mutant human EGFR, the level being selected from the autoantibody of the autoantibody group identifying mutant human EGFR described in the blood sample of wherein this people experimenter raises and indicates nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter.
2. according to the process of claim 1 wherein that described autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, and Seq.Id.No.560.
3., according to the method for any one of claim 1-2, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7, Seq.Id.No.15, Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516, Seq.Id.No.517, Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Scq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599, Seq.Id.No.601, Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
4., according to the method for any one of claim 1-3, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7 and Seq.Id.No.15.
5., according to the method for any one of claim 1-3, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Scq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516 and Seq.Id.No.517.
6., according to the method for any one of claim 1-3, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599 and Seq.Id.No.601.
7. according to the method for any one of claim 1-3, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
8., according to the method for any one of claim 1-7, in the blood sample of wherein this people experimenter, the level of autoantibody is higher than the level of the described autoantibody representing health population people experimenter 5 times.
9. Erlotinib (Erlotinib) or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate, it is used for the treatment of the NSCLC patient identified by the method for any one of claim 1 to 8, comprise and Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate are used to this patient.
10. autoantibody is for predicting that NSCLC patient is to Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate, the purposes of the response for the treatment of, and this antibody is identified by the method for any one of claim 1 to 8.
11. 1 kinds for detecting the test kit that one or more are selected from the level of the autoantibody of the autoantibody group identifying mutant human EGFR in the blood sample of people experimenter, the level being selected from the autoantibody of the autoantibody group identifying mutant human EGFR described in the blood sample of wherein this people experimenter raises and indicates nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter.
12. according to the test kit of claim 11, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, and Seq.Id.No.560.
13. according to the test kit of claim 11, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7 and Seq.Id.No.15.
14. according to the test kit of claim 11, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Scq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516 and Seq.Id.No.517.
15. according to the test kit of claim 11, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599 and Seq.Id.No.601.
16. according to the test kit of claim 11, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
The method of 17. 1 kinds of diagnosing non-small cell lung cancers in people experimenter, it comprises:
In the blood sample of this people experimenter, measure the level of autoantibody being selected from the autoantibody group identifying Human epidermal growth factor receptor, the level being selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor described in the blood sample of wherein this people experimenter raises and indicates nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter.
18. according to the method for claim 16, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521 and Seq.Id.No.561.
19. according to the method for any one of claim 17-18, and wherein said autoantibody identification is selected from the EGFR peptide of lower group:
Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.3, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7, Seq.Id.No.8, Seq.Id.No.9, Seq.Id.No.10, Seq.Id.No.11, Seq.Id.No.12, Seq.Id.No.13, Seq.Id.No.14, Seq.Id.No.15, Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.64, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.102, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.309, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.370, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.373, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516, Seq.Id.No.517, Seq.Id.No.518, Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.525, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.561, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.566, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599, Seq.Id.No.600, Seq.Id.No.601, Seq.Id.No.602, Seq.Id.No.603, Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618, and Seq.Id.No.619.
20. according to the method for any one of claim 19, wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.3, Seq.Id.No.8, Seq.Id.No.9, Seq.Id.No.10, Seq.Id.No.11, Seq.Id.No.12, Seq.Id.No.13, Seq.Id.No.14, Seq.Id.No.64, Seq.Id.No.102, Seq.Id.No.309, Seq.Id.No.370, Seq.Id.No.373, Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, Seq.Id.No.525, Seq.Id.No.556, Seq.Id.No.558, Seq.Id.No.561, Seq.Id.No.566, Seq.Id.No.600, Seq.Id.No.602 and Seq.Id.No.603.
21. according to the method for any one of claim 17-20, and in the blood sample of wherein this people experimenter, the level of autoantibody is higher than the level of the described autoantibody representing health population people experimenter 5 times.
22. Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate, it is used for the treatment of the NSCLC patient identified by the method for any one of claim 17 to 21, comprises and uses Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate to this patient.
23. autoantibodys are for predicting that NSCLC patient is to Erlotinib or its pharmaceutically acceptable salt, particularly Erlotinib hydrochlorate, the purposes of the response for the treatment of, and this antibody is identified by the method for any one of claim 17 to 21.
24. 1 kinds for detecting the test kit of level that one or more are selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor in the blood sample of people experimenter, the level being selected from the autoantibody of the autoantibody group identifying Human epidermal growth factor receptor described in the blood sample of wherein this people experimenter raises and indicates nonsmall-cell lung cancer compared with the level of the described autoantibody representing health population people experimenter.
25. according to the test kit of claim 24, wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.3, Seq.Id.No.8, Seq.Id.No.9, Seq.Id.No.10, Seq.Id.No.11, Seq.Id.No.12, Seq.Id.No.13, Seq.Id.No.14, Seq.Id.No.64, Seq.Id.No.102, Seq.Id.No.309, Seq.Id.No.370, Seq.Id.No.373, Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, Seq.Id.No.525, Seq.Id.No.556, Seq.Id.No.558, Seq.Id.No.561, Seq.Id.No.566, Seq.Id.No.600, Seq.Id.No.602 and Seq.Id.No.603.
26. according to the test kit of claim 25, wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, and Seq.Id.No.561.
The method of 27. 1 kinds of diagnosing non-small cell lung cancers in people experimenter, it comprises:
A) in the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying mutant human EGFR,
B) level of more described autoantibody and reference level, and
C) diagnosis of nonsmall-cell lung cancer is provided when the level of described autoantibody exceeds reference level.
The method of 28. 1 kinds of diagnosing non-small cell lung cancers in people experimenter, it comprises:
A) in the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying mutant human EGFR,
B) level of more described autoantibody and reference level, and
C) treatment is recommended when the level of described autoantibody exceeds reference level.
29. according to the method for claim 27 or 28, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.556, Seq.Id.No.557, Seq.Id.No.558, Seq.Id.No.559, and Seq.Id.No.560.
30. according to the method for any one of claim 28-29, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7, Seq.Id.No.15, Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Scq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516, Seq.Id.No.517, Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599, Seq.Id.No.601, Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
31. according to the method for any one of claim 27-30, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.1, Seq.Id.No.2, Seq.Id.No.4, Seq.Id.No.5, Seq.Id.No.6, Seq.Id.No.7 and Seq.Id.No.15.
32. according to the method for any one of claim 27-30, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.16, Seq.Id.No.17, Seq.Id.No.18, Seq.Id.No.19, Seq.Id.No.20, Seq.Id.No.21, Seq.Id.No.22, Seq.Id.No.23, Seq.Id.No.24, Seq.Id.No.25, Seq.Id.No.26, Seq.Id.No.27, Seq.Id.No.28, Seq.Id.No.29, Seq.Id.No.30, Seq.Id.No.31, Seq.Id.No.32, Seq.Id.No.33, Seq.Id.No.34, Seq.Id.No.35, Seq.Id.No.36, Seq.Id.No.37, Seq.Id.No.38, Seq.Id.No.39, Seq.Id.No.40, Seq.Id.No.41, Seq.Id.No.42, Seq.Id.No.43, Seq.Id.No.44, Seq.Id.No.45, Seq.Id.No.46, Seq.Id.No.47, Seq.Id.No.48, Seq.Id.No.49, Seq.Id.No.50, Seq.Id.No.51, Seq.Id.No.52, Seq.Id.No.53, Seq.Id.No.54, Seq.Id.No.55, Seq.Id.No.56, Seq.Id.No.57, Seq.Id.No.58, Seq.Id.No.59, Seq.Id.No.60, Seq.Id.No.61, Seq.Id.No.62, Seq.Id.No.63, Seq.Id.No.65, Seq.Id.No.66, Seq.Id.No.67, Seq.Id.No.68, Seq.Id.No.69, Seq.Id.No.70, Seq.Id.No.71, Seq.Id.No.72, Seq.Id.No.73, Seq.Id.No.74, Seq.Id.No.75, Seq.Id.No.76, Seq.Id.No.77, Seq.Id.No.78, Seq.Id.No.79, Seq.Id.No.80, Seq.Id.No.81, Seq.Id.No.82, Seq.Id.No.83, Seq.Id.No.84, Seq.Id.No.85, Seq.Id.No.86, Seq.Id.No.87, Seq.Id.No.88, Seq.Id.No.89, Seq.Id.No.90, Seq.Id.No.91, Seq.Id.No.92, Seq.Id.No.93, Seq.Id.No.94, Seq.Id.No.95, Seq.Id.No.96, Seq.Id.No.97, Seq.Id.No.98, Seq.Id.No.99, Seq.Id.No.100, Seq.Id.No.101, Seq.Id.No.103, Seq.Id.No.104, Seq.Id.No.105, Seq.Id.No.106, Seq.Id.No.107, Seq.Id.No.108, Seq.Id.No.109, Seq.Id.No.110, Seq.Id.No.111, Seq.Id.No.112, Seq.Id.No.113, Seq.Id.No.114, Seq.Id.No.115, Seq.Id.No.116, Seq.Id.No.117, Seq.Id.No.118, Seq.Id.No.119, Seq.Id.No.120, Seq.Id.No.121, Seq.Id.No.122, Seq.Id.No.123, Seq.Id.No.124, Seq.Id.No.125, Seq.Id.No.126, Seq.Id.No.127, Seq.Id.No.128, Seq.Id.No.129, Seq.Id.No.130, Seq.Id.No.131, Seq.Id.No.132, Seq.Id.No.133, Seq.Id.No.134, Seq.Id.No.135, Seq.Id.No.136, Seq.Id.No.137, Seq.Id.No.138, Seq.Id.No.139, Seq.Id.No.140, Seq.Id.No.141, Seq.Id.No.142, Seq.Id.No.143, Seq.Id.No.144, Seq.Id.No.145, Seq.Id.No.146, Seq.Id.No.147, Seq.Id.No.148, Seq.Id.No.149, Seq.Id.No.150, Seq.Id.No.151, Seq.Id.No.152, Seq.Id.No.153, Seq.Id.No.154, Seq.Id.No.155, Seq.Id.No.156, Seq.Id.No.157, Seq.Id.No.158, Seq.Id.No.159, Seq.Id.No.160, Seq.Id.No.161, Seq.Id.No.162, Seq.Id.No.163, Seq.Id.No.164, Seq.Id.No.165, Seq.Id.No.166, Seq.Id.No.167, Seq.Id.No.168, Seq.Id.No.169, Seq.Id.No.170, Seq.Id.No.171, Seq.Id.No.172, Seq.Id.No.173, Seq.Id.No.174, Seq.Id.No.175, Seq.Id.No.176, Seq.Id.No.177, Seq.Id.No.178, Seq.Id.No.179, Seq.Id.No.180, Seq.Id.No.181, Seq.Id.No.182, Seq.Id.No.183, Seq.Id.No.184, Seq.Id.No.185, Seq.Id.No.186, Seq.Id.No.187, Seq.Id.No.188, Seq.Id.No.189, Seq.Id.No.190, Seq.Id.No.191, Seq.Id.No.192, Seq.Id.No.193, Seq.Id.No.194, Seq.Id.No.195, Seq.Id.No.196, Seq.Id.No.197, Seq.Id.No.198, Seq.Id.No.199, Seq.Id.No.200, Seq.Id.No.201, Seq.Id.No.202, Seq.Id.No.203, Seq.Id.No.204, Seq.Id.No.205, Seq.Id.No.206, Seq.Id.No.207, Seq.Id.No.208, Seq.Id.No.209, Seq.Id.No.210, Seq.Id.No.211, Seq.Id.No.212, Seq.Id.No.213, Seq.Id.No.214, Seq.Id.No.215, Seq.Id.No.216, Seq.Id.No.217, Seq.Id.No.218, Seq.Id.No.219, Seq.Id.No.220, Seq.Id.No.221, Seq.Id.No.222, Seq.Id.No.223, Seq.Id.No.224, Seq.Id.No.225, Seq.Id.No.226, Seq.Id.No.227, Seq.Id.No.228, Seq.Id.No.229, Seq.Id.No.230, Seq.Id.No.231, Seq.Id.No.232, Seq.Id.No.233, Seq.Id.No.234, Seq.Id.No.235, Seq.Id.No.236, Seq.Id.No.237, Seq.Id.No.238, Seq.Id.No.239, Seq.Id.No.240, Seq.Id.No.241, Seq.Id.No.242, Seq.Id.No.243, Seq.Id.No.244, Seq.Id.No.245, Seq.Id.No.246, Seq.Id.No.247, Seq.Id.No.248, Seq.Id.No.249, Seq.Id.No.250, Seq.Id.No.251, Seq.Id.No.252, Seq.Id.No.253, Seq.Id.No.254, Seq.Id.No.255, Seq.Id.No.256, Seq.Id.No.257, Seq.Id.No.258, Seq.Id.No.259, Seq.Id.No.260, Seq.Id.No.261, Seq.Id.No.262, Seq.Id.No.263, Seq.Id.No.264, Seq.Id.No.265, Seq.Id.No.266, Seq.Id.No.267, Seq.Id.No.268, Seq.Id.No.269, Seq.Id.No.270, Seq.Id.No.271, Seq.Id.No.272, Seq.Id.No.273, Seq.Id.No.274, Seq.Id.No.275, Seq.Id.No.276, Seq.Id.No.277, Seq.Id.No.278, Seq.Id.No.279, Seq.Id.No.280, Seq.Id.No.281, Seq.Id.No.282, Seq.Id.No.283, Seq.Id.No.284, Seq.Id.No.285, Seq.Id.No.286, Seq.Id.No.287, Seq.Id.No.288, Seq.Id.No.289, Seq.Id.No.290, Seq.Id.No.291, Seq.Id.No.292, Seq.Id.No.293, Seq.Id.No.294, Seq.Id.No.295, Seq.Id.No.296, Seq.Id.No.297, Seq.Id.No.298, Seq.Id.No.299, Seq.Id.No.300, Seq.Id.No.301, Seq.Id.No.302, Seq.Id.No.303, Seq.Id.No.304, Seq.Id.No.305, Seq.Id.No.306, Seq.Id.No.307, Seq.Id.No.308, Seq.Id.No.310, Seq.Id.No.311, Seq.Id.No.312, Seq.Id.No.313, Seq.Id.No.314, Seq.Id.No.315, Seq.Id.No.316, Seq.Id.No.317, Seq.Id.No.318, Seq.Id.No.319, Seq.Id.No.320, Seq.Id.No.321, Seq.Id.No.322, Seq.Id.No.323, Seq.Id.No.324, Seq.Id.No.325, Seq.Id.No.326, Seq.Id.No.327, Seq.Id.No.328, Seq.Id.No.329, Seq.Id.No.330, Seq.Id.No.331, Seq.Id.No.332, Seq.Id.No.333, Seq.Id.No.334, Seq.Id.No.335, Seq.Id.No.336, Seq.Id.No.337, Seq.Id.No.338, Seq.Id.No.339, Seq.Id.No.340, Seq.Id.No.341, Seq.Id.No.342, Seq.Id.No.343, Seq.Id.No.344, Seq.Id.No.345, Seq.Id.No.346, Seq.Id.No.347, Seq.Id.No.348, Seq.Id.No.349, Seq.Id.No.350, Seq.Id.No.351, Seq.Id.No.352, Seq.Id.No.353, Seq.Id.No.354, Seq.Id.No.355, Seq.Id.No.356, Seq.Id.No.357, Seq.Id.No.358, Seq.Id.No.359, Seq.Id.No.360, Seq.Id.No.361, Seq.Id.No.362, Seq.Id.No.363, Seq.Id.No.364, Seq.Id.No.365, Seq.Id.No.366, Seq.Id.No.367, Seq.Id.No.368, Seq.Id.No.369, Seq.Id.No.371, Seq.Id.No.372, Seq.Id.No.374, Seq.Id.No.375, Seq.Id.No.376, Seq.Id.No.377, Seq.Id.No.378, Seq.Id.No.379, Seq.Id.No.380, Seq.Id.No.381, Seq.Id.No.382, Seq.Id.No.383, Seq.Id.No.384, Seq.Id.No.385, Seq.Id.No.386, Seq.Id.No.387, Seq.Id.No.388, Seq.Id.No.389, Seq.Id.No.390, Seq.Id.No.391, Seq.Id.No.392, Seq.Id.No.393, Seq.Id.No.394, Seq.Id.No.395, Seq.Id.No.396, Seq.Id.No.397, Seq.Id.No.398, Seq.Id.No.399, Seq.Id.No.400, Seq.Id.No.401, Seq.Id.No.402, Seq.Id.No.403, Seq.Id.No.404, Seq.Id.No.405, Seq.Id.No.406, Seq.Id.No.407, Seq.Id.No.408, Seq.Id.No.409, Seq.Id.No.410, Seq.Id.No.411, Seq.Id.No.412, Seq.Id.No.413, Seq.Id.No.414, Seq.Id.No.415, Seq.Id.No.416, Seq.Id.No.417, Seq.Id.No.418, Seq.Id.No.419, Seq.Id.No.420, Seq.Id.No.421, Seq.Id.No.422, Seq.Id.No.423, Seq.Id.No.424, Seq.Id.No.425, Seq.Id.No.426, Seq.Id.No.427, Seq.Id.No.428, Seq.Id.No.429, Seq.Id.No.430, Seq.Id.No.431, Seq.Id.No.432, Seq.Id.No.433, Seq.Id.No.434, Seq.Id.No.435, Seq.Id.No.436, Seq.Id.No.437, Seq.Id.No.438, Seq.Id.No.439, Seq.Id.No.440, Seq.Id.No.441, Seq.Id.No.442, Seq.Id.No.443, Seq.Id.No.444, Seq.Id.No.445, Seq.Id.No.446, Seq.Id.No.447, Seq.Id.No.448, Seq.Id.No.449, Seq.Id.No.450, Seq.Id.No.451, Seq.Id.No.452, Seq.Id.No.453, Seq.Id.No.454, Seq.Id.No.455, Seq.Id.No.456, Seq.Id.No.457, Seq.Id.No.458, Seq.Id.No.459, Seq.Id.No.460, Seq.Id.No.461, Seq.Id.No.462, Seq.Id.No.463, Seq.Id.No.464, Seq.Id.No.465, Seq.Id.No.466, Seq.Id.No.467, Seq.Id.No.468, Seq.Id.No.469, Seq.Id.No.470, Seq.Id.No.471, Seq.Id.No.472, Seq.Id.No.473, Seq.Id.No.474, Seq.Id.No.475, Seq.Id.No.476, Seq.Id.No.477, Seq.Id.No.478, Seq.Id.No.479, Seq.Id.No.480, Seq.Id.No.481, Seq.Id.No.482, Seq.Id.No.483, Seq.Id.No.484, Seq.Id.No.485, Seq.Id.No.486, Seq.Id.No.487, Seq.Id.No.488, Seq.Id.No.489, Seq.Id.No.490, Seq.Id.No.491, Seq.Id.No.492, Seq.Id.No.493, Seq.Id.No.494, Seq.Id.No.495, Seq.Id.No.496, Seq.Id.No.497, Seq.Id.No.498, Seq.Id.No.499, Seq.Id.No.500, Seq.Id.No.501, Seq.Id.No.502, Seq.Id.No.503, Seq.Id.No.504, Seq.Id.No.505, Seq.Id.No.506, Seq.Id.No.507, Seq.Id.No.508, Seq.Id.No.509, Seq.Id.No.510, Seq.Id.No.511, Seq.Id.No.512, Seq.Id.No.513, Seq.Id.No.514, Seq.Id.No.515, Seq.Id.No.516 and Seq.Id.No.517.
33. according to the method for any one of claim 27-30, and wherein said autoantibody identification is selected from the mutant egf R peptide of lower group:
Seq.Id.No.518, Seq.Id.No.522, Seq.Id.No.523, Seq.Id.No.524, Seq.Id.No.526, Seq.Id.No.527, Seq.Id.No.528, Seq.Id.No.529, Seq.Id.No.530, Seq.Id.No.531, Seq.Id.No.532, Seq.Id.No.533, Seq.Id.No.534, Seq.Id.No.535, Seq.Id.No.536, Seq.Id.No.537, Seq.Id.No.538, Seq.Id.No.539, Seq.Id.No.540, Seq.Id.No.541, Seq.Id.No.542, Seq.Id.No.543, Seq.Id.No.544, Seq.Id.No.545, Seq.Id.No.546, Seq.Id.No.547, Seq.Id.No.548, Seq.Id.No.549, Seq.Id.No.550, Seq.Id.No.551, Seq.Id.No.552, Seq.Id.No.553, Seq.Id.No.554, Seq.Id.No.555, Seq.Id.No.557, Seq.Id.No.559, Seq.Id.No.560, Seq.Id.No.562, Seq.Id.No.563, Seq.Id.No.564, Seq.Id.No.565, Seq.Id.No.567, Seq.Id.No.568, Seq.Id.No.569, Seq.Id.No.570, Seq.Id.No.571, Seq.Id.No.572, Seq.Id.No.573, Seq.Id.No.574, Seq.Id.No.575, Seq.Id.No.576, Seq.Id.No.577, Seq.Id.No.578, Seq.Id.No.579, Seq.Id.No.580, Seq.Id.No.581, Seq.Id.No.582, Seq.Id.No.583, Seq.Id.No.584, Seq.Id.No.585, Seq.Id.No.586, Seq.Id.No.587, Seq.Id.No.588, Seq.Id.No.589, Seq.Id.No.590, Seq.Id.No.591, Seq.Id.No.592, Seq.Id.No.593, Seq.Id.No.594, Seq.Id.No.595, Seq.Id.No.596, Seq.Id.No.597, Seq.Id.No.598, Seq.Id.No.599 and Seq.Id.No.601.
34. according to the method for any one of claim 27-30, wherein said autoantibody identification is selected from the mutant egf R peptide of lower group: Seq.Id.No.604, Seq.Id.No.605, Seq.Id.No.606, Seq.Id.No.607, Seq.Id.No.608, Seq.Id.No.609, Seq.Id.No.610, Seq.Id.No.611, Seq.Id.No.612, Seq.Id.No.613, Seq.Id.No.614, Seq.Id.No.615, Seq.Id.No.616, Seq.Id.No.617, Seq.Id.No.618 and Seq.Id.No.619.
35. according to the method for any one of claim 27-34, and in the blood sample of wherein this people experimenter, the level of autoantibody is higher than the level of the described autoantibody representing health population people experimenter 5 times.
The method of 36. 1 kinds of diagnosing non-small cell lung cancers in people experimenter, it comprises:
A) in the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying Human epidermal growth factor receptor,
B) level of more described autoantibody and reference level, and
C) diagnosis of nonsmall-cell lung cancer is provided when the level of described autoantibody exceeds reference level.
The method of 37. 1 kinds of diagnosing non-small cell lung cancers in people experimenter, it comprises:
A) in the blood sample of this people experimenter, measure the level of the autoantibody being selected from the autoantibody group identifying Human epidermal growth factor receptor,
B) level of more described autoantibody and reference level, and
C) treatment is recommended when the level of described autoantibody exceeds reference level.
38. according to the method for claim 36 or 37, wherein said autoantibody identification is selected from the EGFR peptide of lower group: Seq.Id.No.3, Seq.Id.No.8, Seq.Id.No.9, Seq.Id.No.10, Seq.Id.No.11, Seq.Id.No.12, Seq.Id.No.13, Seq.Id.No.14, Seq.Id.No.64, Seq.Id.No.102, Seq.Id.No.309, Seq.Id.No.370, Seq.Id.No.373, Seq.Id.No.519, Seq.Id.No.520, Seq.Id.No.521, Seq.Id.No.525, Seq.Id.No.556, Seq.Id.No.558, Seq.Id.No.561, Seq.Id.No.566, Seq.Id.No.600, Seq.Id.No.602 and Seq.Id.No.603.
39. according to the method for any one of claim 36-38, and in the blood sample of wherein this people experimenter, the level of autoantibody is higher than the level of the described autoantibody representing health population people experimenter 5 times.
40. according to the method for claim 28-35, any one of 37-39, and wherein said treatment is Erlotinib.
The invention described in 41. description.
CN201380027063.XA 2012-06-07 2013-06-04 Autoimmune antibodies Pending CN104334190A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12171126.1 2012-06-07
EP12171126 2012-06-07
PCT/EP2013/061430 WO2013182537A1 (en) 2012-06-07 2013-06-04 Autoimmune antibodies

Publications (1)

Publication Number Publication Date
CN104334190A true CN104334190A (en) 2015-02-04

Family

ID=48570148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380027063.XA Pending CN104334190A (en) 2012-06-07 2013-06-04 Autoimmune antibodies

Country Status (11)

Country Link
US (1) US20130331287A1 (en)
EP (1) EP2858669A1 (en)
JP (1) JP2015527564A (en)
KR (1) KR20150017344A (en)
CN (1) CN104334190A (en)
BR (1) BR112014028659A2 (en)
CA (1) CA2870015A1 (en)
HK (1) HK1202241A1 (en)
MX (1) MX2014014829A (en)
RU (1) RU2014154144A (en)
WO (1) WO2013182537A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114790235A (en) * 2021-01-26 2022-07-26 南通睿科医药科技有限公司 Neoantigen aiming at EGFR exon 19 deletion mutation and application thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015117951A1 (en) * 2014-02-04 2015-08-13 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against egf-receptor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073905A1 (en) * 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2530172A1 (en) * 2003-06-27 2005-02-10 Abgenix, Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
KR20090074202A (en) * 2006-09-18 2009-07-06 베링거 인겔하임 인터내셔날 게엠베하 Method for treating cancer harboring EGFR mutations
WO2010073905A1 (en) * 2008-12-25 2010-07-01 シャープ株式会社 Moving image viewing apparatus
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011073905A1 (en) * 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
李元: ""应用多肽芯片研究非小细胞肺癌患者血清中的EGFR自身抗体"", 《中国肺癌杂志》 *
李元: ""肺癌患者血清中EGFR和HER-2自身抗体的研究进展"", 《中国肺癌杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114790235A (en) * 2021-01-26 2022-07-26 南通睿科医药科技有限公司 Neoantigen aiming at EGFR exon 19 deletion mutation and application thereof

Also Published As

Publication number Publication date
EP2858669A1 (en) 2015-04-15
US20130331287A1 (en) 2013-12-12
BR112014028659A2 (en) 2017-07-25
MX2014014829A (en) 2015-02-12
KR20150017344A (en) 2015-02-16
CA2870015A1 (en) 2013-12-12
RU2014154144A (en) 2016-07-27
HK1202241A1 (en) 2015-09-25
JP2015527564A (en) 2015-09-17
WO2013182537A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
JP7531217B2 (en) Cell-free DNA for assessing and/or treating cancer - Patents.com
Kitazono et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non–small-cell lung cancer
Benjamin Larman et al. Cytosolic 5′‐nucleotidase 1A autoimmunity in sporadic inclusion body myositis
CN104662171B (en) Individualized cancer vaccine and adoptive immunity cell therapy
Blyth et al. Progress and challenges in Mesothelioma: From bench to bedside
Ohba et al. Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab
US20180340944A1 (en) Methods for Treating Breast Cancer and for Identifying Breast Cancer Antigens
CN104703620A (en) Method of diagnosis and treatment
Weiss et al. Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: Correlates with expression and quantification on metastases using 64Cu-plerixafor PET
Dettling et al. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as novel and frequent T-cell targets in human IDH-mutant glioma
US20190249261A1 (en) Methods For Identifying Clonal Mutations And Treating Cancer
AU2016270686A1 (en) Quantifying Her2 protein for optimal cancer therapy
CN103717616A (en) Mutations in the epidermal growth factor receptor gene
Mallikarjuna et al. VHL status regulates transforming growth factor-β signaling pathways in renal cell carcinoma
Xu et al. Utilizing tumor and plasma liquid biopsy in treatment decision making for an estrogen receptor-positive advanced breast cancer patient
García-Sancha et al. Overcoming resistance to immunotherapy in advanced cutaneous squamous cell carcinoma
Weidner et al. Translocator protein (18kDA)(TSPO) marks mesenchymal glioblastoma cell populations characterized by elevated numbers of tumor-associated macrophages
Baysac et al. PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants
JP2020522501A (en) Prediction method of cancer treatment results by T-DM1
CN104334190A (en) Autoimmune antibodies
Perera et al. Detection of human leukocyte antigen class I loss of heterozygosity in solid tumor types by next-generation DNA sequencing
CA3140204A1 (en) Hla tumor antigen peptides of class i and ii for treating mammary/breast carcinomas
Maurício et al. Relationship between sarcopenia and mTOR pathway in patients with colorectal cancer: preliminary report
Cruz et al. Nucleolin as a potential biomarker for canine malignant neoplasia
ES2960872T3 (en) A method to diagnose cancers of the genitourinary tract

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202241

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150204

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1202241

Country of ref document: HK